Imdusiran + Durvalumab

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hepatitis B, Chronic

Conditions

Hepatitis B, Chronic

Trial Timeline

May 1, 2024 → Aug 1, 2024

NCT ID

NCT06245291

About Imdusiran + Durvalumab

Imdusiran + Durvalumab is a phase 2 stage product being developed by Arbutus Biopharma for Hepatitis B, Chronic. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06245291. Target conditions include Hepatitis B, Chronic.

What happened to similar drugs?

20 of 20 similar drugs in Hepatitis B, Chronic were approved

Approved (20) Terminated (8) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Pegylated Interferon + RibavirinAstellas PharmaApproved

✅Glecaprevir-pibrentasvirAbbVieApproved

✅ABT450r-ABT267-ABT333 +/- RibavirinAbbVieApproved

✅PTV/r/OBV/DSVAbbVieApproved

✅SOF/LDV (sofosbuvir/ledipasvir) + PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) + EBR/GZR (elbasvir/grazoprevir) + RibavirinAbbVieApproved

✅OBV/PTV/r and DSV + Placebo to match OBV/PTV/r and DSVAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06245291	Phase 2	Withdrawn	May 1, 2024	Aug 1, 2024	Hepatitis B, Chronic

Competing Products

20 competing products in Hepatitis B, Chronic

See all competitors

Product	Company	Stage	Hype Score
VK2809 + Placebos	Viking Therapeutics	Phase 2	32
TERN-501 + TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-201	Terns Pharmaceuticals	Phase 1	26
IVA337 + IVA337 + Placebo	Inventiva	Phase 2	29
IVA337 + Placebo + Empagliflozin	Inventiva	Phase 2	29
IVA337 + Placebo	Inventiva	Phase 3	41
Pegasys® + Pegasys®	Chugai Pharmaceutical	Approved	43
peginterferon alfa-2a + rivavirin	Chugai Pharmaceutical	Phase 3	40
SOF + COPE	Chugai Pharmaceutical	Pre-clinical	26
Colesevelam Hcl	Daiichi Sankyo	Phase 2	35
ASP9831 + Placebo	Astellas Pharma	Phase 2	35
FK788	Astellas Pharma	Phase 2	35
MK-2248	Merck	Phase 1	29
Interferon alfacon-1	Astellas Pharma	Phase 3	40
Pegylated Interferon + Ribavirin	Astellas Pharma	Approved	35
Tacrolimus + steroids, monoclonal anti-IL2R antibody	Astellas Pharma	Phase 2	35
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	29
Dolutegravir + Methadone	Shionogi	Phase 1	29
Clevudine + Adefovir	Eisai	Phase 3	40